Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration‐resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance)

Publisher： John Wiley & Sons Inc

ISSN： 0008-543x

Source： CANCER, Vol.121, Iss.7, 2015-04, pp. : 1025-1031

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration‐resistant prostate cancer

By  

BJU INTERNATIONAL, Vol. 118, Iss. 4, 2016-10 ,pp. : 590-597

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety of enzalutamide in patients with metastatic castration‐resistant prostate cancer previously treated with docetaxel: Expanded access in North America

By  

THE PROSTATE, Vol. 75, Iss. 8, 2015-06 ,pp. : 836-844

John Wiley & Sons Inc

Access to resources Recommend Favorite

Metabolic syndrome in castration‐resistant prostate cancer patients treated with abiraterone

By  

THE PROSTATE, Vol. 75, Iss. 12, 2015-07 ,pp. : 1329-1338

John Wiley & Sons Inc

Access to resources Recommend Favorite

Is prostate cancer changing?: Evolving patterns of metastatic castration‐resistant prostate cancer

By  

CANCER, Vol. 120, Iss. 6, 2014-03 ,pp. : 833-839

John Wiley & Sons Inc

Access to resources Recommend Favorite

Final quality of life and safety data for patients with metastatic castration‐resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279)

By  

BJU INTERNATIONAL, Vol. 116, Iss. 6, 2015-12 ,pp. : 880-887

John Wiley & Sons Inc

Access to resources Recommend Favorite